Lucy Lu Insider Information
Lucy Lu, M.D. rejoins the Veru Board in May 2021 after previously serving as a Director of the Company from 2016 to 2019. Dr. Lu is the President and Chief Executive Officer of Avenue Therapeutics, Inc. From 2012 to 2017, Dr. Lu was the Chief Financial Officer of Fortress Biotech, Inc. Prior to working in the biotech industry, Dr. Lu had 10 years of experience in healthcare-related equity research and investment banking. From 2007 to 2012, Dr. Lu was a senior biotechnology equity analyst with Citigroup Investment Research. Dr. Lu holds an M.D. degree from the New York University School of Medicine and an M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee’s College of Arts and Science.
What is Lucy Lu's net worth?
The estimated net worth of Lucy Lu is at least $66,900.00 as of May 11th, 2017. Dr. Lu owns 5,000 shares of Veru stock worth more than $66,900 as of May 22nd. This net worth estimate does not reflect any other investments that Dr. Lu may own. Learn More about Lucy Lu's net worth.
How do I contact Lucy Lu?
Has Lucy Lu been buying or selling shares of Veru?
Lucy Lu has not been actively trading shares of Veru over the course of the past ninety days. As far as recent transactions, 0 shares of the company's stock in a transaction on Sunday, May 22nd. Learn More on Lucy Lu's trading history.
Who are Veru's active insiders?
Are insiders buying or selling shares of Veru?
During the last year, Veru insiders bought shares 1 times. They purchased a total of 4,800 shares worth more than $32,544.00. During the last year, insiders at the sold shares 1 times. They sold a total of 100,000 shares worth more than $835,000.00. The most recent insider tranaction occured on August, 17th when Director Lucy Lu bought 4,800 shares worth more than $32,544.00. Insiders at Veru own 23.1 % of the company.
Learn More about insider trades at Veru. Information on this page was last updated on 8/17/2021.
Lucy Lu Insider Trading History at Veru
| Transaction Date | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/17/2021 | Buy | 4,800 | $6.78 | $32,544.00 | |  |
| 5/11/2017 | Buy | 5,000 | $1.00 | $5,000.00 | 5,000 | |
Veru Company Overview
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Read More
Today's Range
Now:
$13.38
Volume
11,547,512 shs
Average Volume
24,788,880 shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
